Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

retaspimycin (IPI-504)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Infinity Pharma

Drug class:

HSP90 inhibitor

Related drugs:

ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	IPI-504 Sensitive: D – Preclinical IPI-504 Sensitive : D	IPI-504 Sensitive: D – Preclinical IPI-504 Sensitive : D
KRAS G12D + TP53 deletion	Lung Adenocarcinoma	KRAS G12D + TP53 deletion	Lung Adenocarcinoma	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
TP53 deletion	Colorectal Cancer	TP53 deletion	Colorectal Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
TP53 deletion	Non Small Cell Lung Cancer	TP53 deletion	Non Small Cell Lung Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D